Background. Excess mortality has decreased among human immunodeficiency virus (HIV)-infected patients but without evidence of a decrease among patients with AIDS. We assessed temporal changes in excess mortality and elucidated risk factors for excess mortality in patients with AIDS diagnosed in the era of highly active antiretroviral therapy (HAART).
infected patients. Accounting for such variability can help formulate strategies on how to optimize HIV care.
Although HAART use has dramatically decreased death rates among persons with AIDS [6] , it is unknown to what extent HAART-related decreases in excess mortality observed among HIV-infected persons exist among patients with AIDS. Also, although the recent analysis of the CASCADE cohorts was based on a large number of patients, covariates evaluated to assess the risks for excess mortality included only age at seroconversion, sex, and HIV exposure category. Other, potentially more important correlates of mortality, such as CD4 + T cell count, presence of cytomegalovirus (CMV) retinitis, and quantitative plasma HIV RNA level (viral load), have not been explored. The Longitudinal Study of Ocular Complications in AIDS (LSOCA), funded by the National Eye Institute, is one of a few cohort studies limited to persons diagnosed with AIDS but without further exclusion criteria [8, 9] . Our aims here are to assess the extent of the decrease in excess mortality over time and to elucidate risk factors for excess mortality among patients participating in LSOCA who have been diagnosed with AIDS in the HAART era, compared with among persons in the general US population.
METHODS
LSOCA is a prospective observational study of patients with AIDS, who were at least 13 years of age at enrollment [8, 9] . Enrollees have AIDS diagnosed according to the 1993 Centers for Disease Control and Prevention case surveillance definition of AIDS. Patients with incident and prevalent AIDS are included. Since September 1998, recruitment has been performed at 19 clinical centers across the United States, located in urban areas with sizable HIV-infected populations. The study protocol was reviewed and approved by institutional review boards at each of the participating clinics and the coordinating center. The study is conducted in accordance with the principles of the Declaration of Helsinki. Adult patients provide written informed consent. For adolescents, a consent statement is signed by parents or guardians and an assent statement is signed by adolescents and their parents or guardians. At enrollment, all participants provide a medical history, including information on AIDS-related illnesses and antiretroviral therapy, and undergo an ophthalmologic examination. Laboratory tests performed at enrollment and follow-up include hematology tests, lymphocyte subset analysis, and in patients with a major ocular complication, serum chemistry tests. More detailed information about the study protocol, data forms and the study handbook is available at the LSOCA Web site (http:// www.lsoca.com).
In this analysis, we included patients enrolled during the period from January 1999 through December 2007 who received a diagnosis of AIDS during the HAART era (from January 1996 onwards). We did not consider the year 1998 in the analyses because recruitment had just started, with too few patients enrolled (n p 9) to provide a meaningful comparison to the death rates of the general population. We excluded the year 2008 from the analyses because of the as-yet incomplete reporting of final death data to the data coordination center. We also excluded patients aged !25 years (n p 20) or 164 years (n p 15), because a comparison of these age groups, which would require further stratification into calendar year and sex, against mortality rates of the general US population would be too imprecise. We decided against merging patients in these age groups with other age groups because mortality rates can change substantially from one 5-year category to the next; for example, in 1999, there were 1596 deaths per 100,000 persons among 60-64-year-old men and 2479 deaths per 100,000 persons among 65-70-year-old men). The primary aim of the analysis was to assess decreases in excess mortality among patients with AIDS enrolled in the LSOCA cohort. In an additional analysis, we assessed patient characteristics associated with excess mortality.
We defined excess mortality as the age-, year-, and sex-adjusted difference in mortality rates between patients with AIDS and persons in the US general population. In a first step, we calculated mortality rates for patients enrolled in LSOCA for each calendar year (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) ) and compared them with mortality rates for the US population, adjusting for calendar year, age, and sex. We retrieved the mortality rates of the US population from the Vital Statistics report of the US Center for Disease Control and Prevention [10] . For the years 2006 and 2007, for which mortality rates had not yet been released, we used multiple imputation (the "ice" command in Stata software, version 10.1 for Windows [Stata Corp]) to generate ageand sex-stratified mortality rates for 2006 and 2007. We based the multiple imputation on age-adjusted death rates from the Vital Statistics reports for 1999-2005 (for men and women separately) and used weights to indicate that the death rate estimates are based on a large number of observations. We generated 100 data sets and took the medians as an estimate of the age-and sex-stratified mortality rates for 2006 and 2007. On the basis of these mortality rates, we compared, for each year of follow-up, the observed mortality rates (in the LSOCA cohort) with the mortality rates of the general US population, adjusting for age and sex. We considered matched individuals from the US population to be at risk until the corresponding LSOCA patient died or was censored (using the Ederer II method [11, 12] ). To quantify the average extent of the decrease in mortality rates per year, we used Poisson regression analysis, with the number of excess deaths as the dependent variable and the calendar year as independent variable; we reported the mean annual decrease as a percentage. In addition, we extracted the number of excess deaths, observation time, and excess mortality per 1000 person-years from the publication on excess mortality in the CASCADE cohort to compare (decreases in) excess mortality observed among patients with AIDS (in the LSOCA cohort) and overall HIV-infected patients (in the CAS-CADE cohorts).
We stratified the analysis for moderate-to-high and for low CD4 + cell count (у200 vs !200 cells/mL) at enrollment, reflecting the long-term prognosis based on CD4 + counts. We conducted a number of sensitivity analyses to further assess the association of CD4 + cell count status (у or ! 200 cells/mL) and change of excess mortality over time. First, we repeated the analysis excluding the years 1999 and 2000 because of the low number of enrollees in these years. Second, we considered CD4 + cell counts for individual patients for each year of observation after enrollment (ie, with no time lag between CD4 + cell count measurement and year of observation), because CD4 + cell counts vary in individuals over time (with and without receipt of HAART). This analysis reflects the immediate association between CD4
+ cell counts and mortality. Third, we also considered 2-and 4-year lags between CD4 + cell count measurements and year of observation. Finally, we also planned to stratify the analysis for nadir CD4 + cell count before enrollment into LSOCA, but the number of patients with nadir CD4 + cell count у200 cells/mL was too low to provide a meaningful analysis.
To assess the association of potential risk factors with excess mortality we used a Poisson regression model while offsetting the expected deaths, which adjusts for the mortality observed in the general population (background mortality) [12, 13] . The model provides estimates of excess risk ratios, where the interpretation is similar to that of the risk ratio. The risk factors included age, sex, race (white, black, or other), type of HIV exposure group (men who have sex with men, injection drug user, and other), CD4
+ cell count at enrollment into LSOCA (!200, 200-499 , and у500 cells/mL), nadir CD4 + cell count (!100 vs у100 cells/mL), plasma HIV RNA level at enrollment (!400 vs у400 copies/mL), CMV retinitis, time since AIDS diagnosis, and calendar year of enrollment. To include all eligible patients in the analyses, we assumed that the viral load was 1400 copies/mL for the 64 patients (5.4%) with missing data at study enrollment. We had complete data for the other variables. All analyses were conducted using Stata software, version 10.1 (Stata Corp).
RESULTS
As of 31 December 2008, there were 2221 patients enrolled into LSOCA. We included 1188 patients in the present analysis who received a diagnosis of AIDS during the HAART era and enrolled into LSOCA during the period January 1999 through December 2007. We excluded patients who received a diagnosis of AIDS before 1996 (n p 863), who enrolled in 1998 (n p 9) or in 2008 (n p 90), who had a missing date of AIDS diagnosis (n p 36), and who were aged !25 years (n p 20) or 164 years (n p 15).
Patients were predominantly male (76.2%), were of nonHispanic white (38.9%) or black ethnicity (41.4%), and had received a diagnosis of AIDS 11 year before enrollment in LSOCA (61.6%) ( (Figure 1 ). On the basis of a Poisson regression model, the mean annual decrease was 8.0% (95% CI, 3.0%-12.7%; P p .002). Excess mortality in the CASCADE HIV cohorts averaged 9.1 excess deaths per 1000 person-years during 1999-2005, the mean annual decrease in excess mortality among HIV-infected patients enrolled in the CASCADE cohorts was 4.8% (95% CI, 3.1%-6.5%; P ! .001).
For patients with a low CD4 + cell count (!200 cells/mL), the mean excess mortality rate per year was 74.0 deaths per 1000 patient-years (95% CI, 64.5-84.4 deaths per 1000 patientyears); among patients with a moderate-to-high CD4 + cell count (у200 cells/mL), it was 21.1 deaths per 1000 patientyears (95% CI, 15.5-28.1 deaths per 1000 patient-years) ( Figure  2 ). Excess mortality decreased substantially among patients with a low CD4 + cell count during the period 1999-2007 (8.3% per year; 95% CI, 2.7%-13.4% per year; P p .004), whereas there was no decrease among patients with moderate-to-high CD4 + cell counts (1.4%; 95% CI, Ϫ10.7% to 15.3%; P p .83). The interaction between CD4 + cell count status and year was not statistically significant (P p .16) .
In the sensitivity analysis here, we only considered the years 2001-2007; excess mortality decreased by 11.4% per year (8.3%; 95% CI, 4.8%-17.5%; P p .001) among patients with a low CD4 + cell count, whereas there was no decrease among patients Risk factors for excess mortality among patients with AIDS. A high plasma HIV RNA level (1400 copies/mL) and low CD4 + cell count (!200 cells/mL) were the strongest independent factors (Table 2) in the relative survival model based on Poisson regression and were independently associated with a ∼3-fold increased risk of excess mortality (Table 2) . Patients with CMV retinitis, who were not receiving HAART, who had a longer duration since AIDS diagnosis, and who had enrolled early in LSOCA were also at statistically significantly higher risk of excess mortality. We did not find a statistically significant association between sex, age, race, and HIV exposure category with excess mortality.
The number of excess deaths per 1000 person-years varied greatly depending on the presence of the 3 strongest risk factors for increased excess mortality (plasma HIV RNA level 1400 copies/mL, CD4 + cell count !200 cells/mL, and CMV retinitis) ( Table   3 ). For example, patients with none of these risk factors experienced 8 excess deaths per 1000 person-years (95% CI, 5-16 excess deaths per 1000 person-years), compared with 128 excess deaths per 1000 person-years (95% CI, 82-201 excess deaths per 1000 person-years) among patients with all 3 risk factors.
DISCUSSION
Among persons who initiated HAART after having received a diagnosis of AIDS, excess mortality was nearly halved between 1999 and 2007 but remained high, with 36 excess deaths per 1000 person-years in 2007. Excess mortality was thus, on average, 15 times higher than rates seen among HIV-infected patients in the CASCADE study [1] . The mortality rates observed in LSOCA closely reflect those of the entire US AIDS population. The Centers for Disease Control and Prevention reported a mortality rate of 56.3 deaths per 1000 person-years in 1999, with a decrease to 30.0 deaths per 1000 person-years in 2007 [14] . The extent of excess mortality was linked to the presence of identifiable mortality risk factors. Calendar year, time since AIDS diagnosis, higher plasma HIV RNA level, lower CD4 + cell count, and diagnosis of CMV retinitis were each independent risk factors for excess mortality. Depending on the presence of the latter 3 risk factors, the extent of excess mortality seen in patients with AIDS ranged from 8 excess deaths per 1000 patient-years (twice as many as observed among all HIV-infected patients) to 128 excess deaths per 1000 + cell counts, with 95% confidence intervals (CIs). The dashed line represents the fitting line based on a Poisson regression model, which showed an average annual decline in excess mortality of 8.3% (95% CI, 2.7%-13.4%;P p .004). The lower line in the graph shows the number of excess deaths per 1000 person-years (solid rectangles) in patients with moderate to high CD4 + cell counts at study enrollment, and 95% CIs. The dotted line represents the fitting line based on a Poisson regression model. There was no change in excess mortality (1.4%; 95% CI, Ϫ10.7% to 15.3%; P p .83). The interaction between CD4 + cell count status and year was not statistically significant (P p .16).
patient-years (16 times that observed among all HIV-infected patients) [1] .
Previous studies have demonstrated that HIV-related mortality rates have markedly decreased as a consequence of the introduction and prevalent use of HAART [6, 7, 15] . Results from CASCADE further demonstrated that mortality rate decreases were progressive through the first decade of the HAART era despite stability in HAART use rates [1] . Potential reasons for continued decreases in mortality rates include improvements in overall health care for HIV-infected persons, earlier identification of HIV infection (making earlier HAART initiation possible), trends toward earlier HAART use in general, more attention to patient adherence, and improvements in the efficacy and tolerability of specific antiretroviral therapies available. Our results suggest that, among patients with AIDS, the effects of improvements in HAART management might be even more pronounced. The decrease in excess mortality that we observed is likely a consequence of progressive optimization of antiretroviral management (eg, timing of therapy initiation or specific drug combinations used) rather than an increased rate of HAART use overall; the proportion of patients receiving HAART did not change between 1999 and 2007.
The stratified analyses suggested a possible association of CD4 + cell count and excess mortality. Although this analysis was limited by the sample size, and although the interaction between CD4 + cell count and year was not statistically significant in neither the main nor in 2 sensitivity analyses, it is remarkable that there was differential decrease in excess mortality depending on CD4 + cell counts. A possible explanation that needs more evidence than provided by our study could be that further mortality reductions among patients with AIDS who had higher CD4
+ counts becoming increasingly difficult, even with the use of more effective treatment, or is going to require substantially longer periods of follow-up.
The main limitation of our analysis was sample size. Our estimates of excess mortality suffer from a lack of precision, as do the analyses stratified for CD4 + cell count. Another limitation of the present analyses is the focus on opportunistic infections of the eyes, which may be overrepresented among all opportunistic infections in LSOCA patients. We did not assess the (competing) risk of different opportunistic infections for excess mortality. There is, however, very limited evidence on the prevalence of opportunistic infections and their association with prognosis in patients with AIDS from the United Receipt of HAART (no vs yes) 1.61 (1.23-2.12) .001
NOTE. HAART, highly active antiretroviral therapy. a The CD4 + T cell count categories of 200-499 and у500 cells/mL were merged into у200 cells/ mL because they were similarly associated with excess deaths in the multiple Poisson regression model. States. Furthermore, we did not explore the influence of additional factors on mortality, such as use of specific types of HAART, because this was beyond the scope of this article. Finally, like most analyses on excess mortality, we focused on allcause mortality, which informs public health on changes in mortality at a population level and may serve as an index of the effectiveness of antiretroviral treatment. However, mortality among HAART-treated patients clearly may not only be due to AIDS-related conditions; it is also (and increasingly) a consequence of comorbid conditions [5, 16] .
In conclusion, our study demonstrated that excess mortality among patients with AIDS was nearly halved in the HAART era and was most strongly linked to stage of HIV disease. These results reflect the continuing improvements in AIDS management but also highlight that excess mortality remains ∼5 times higher than in HIV-infected patients without AIDS.
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